Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Corcept Therapeutics ( (CORT) ) has issued an update.
On January 22, 2026, Corcept Therapeutics reported that its pivotal Phase 3 ROSELLA trial of relacorilant plus nab-paclitaxel in patients with platinum-resistant ovarian cancer met its overall survival primary endpoint, with the combination reducing the risk of death by 35% versus nab-paclitaxel alone and extending median overall survival to 16.0 months from 11.9 months, without adding safety burden compared with chemotherapy alone. The trial, which previously met its progression-free survival primary endpoint and enrolled 381 patients across multiple regions, strengthens relacorilant’s clinical profile as an oral, biomarker-agnostic therapy that could reshape the treatment landscape for platinum-resistant ovarian cancer and supports Corcept’s ongoing regulatory reviews in the U.S. and Europe, as well as its broader development strategy for relacorilant and other cortisol modulators in solid tumors and hypercortisolism.
The most recent analyst rating on (CORT) stock is a Buy with a $90.00 price target. To see the full list of analyst forecasts on Corcept Therapeutics stock, see the CORT Stock Forecast page.
Spark’s Take on CORT Stock
According to Spark, TipRanks’ AI Analyst, CORT is a Neutral.
The score is supported primarily by strong underlying financial strength (especially the low-leverage balance sheet) and constructive earnings-call fundamentals (revenue growth and raised guidance). It is weighed down by very bearish technicals, a premium P/E with no dividend support, and heightened regulatory risk after the relacorilant FDA Complete Response Letter.
To see Spark’s full report on CORT stock, click here.
More about Corcept Therapeutics
Corcept Therapeutics, based in Redwood City, California, is a commercial-stage biopharmaceutical company focused on discovering and developing medications that modulate the hormone cortisol to treat severe endocrinologic, oncologic, metabolic and neurologic disorders. The company markets Korlym for endogenous hypercortisolism and is advancing a broad pipeline of selective glucocorticoid receptor antagonists, including relacorilant, in indications such as ovarian, endometrial, cervical, pancreatic and prostate cancers, as well as hypercortisolism and other serious diseases.
Average Trading Volume: 1,500,383
Technical Sentiment Signal: Sell
Current Market Cap: $3.71B
For detailed information about CORT stock, go to TipRanks’ Stock Analysis page.